Zydus Lifesciences Limited has informed the Exchange about Rumour Verification - Regulation 30(11)
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences confirmed that the US District Court for the District of Delaware passed an order against the company on April 15, 2025, in a patent validity case filed by Astellas Pharma Inc. The litigation relates to a sustained-release formulation of mirabegron, marketed by Astellas under the brand Myrbetriq®. The company stated this court order is what caused the sharp movement in its share price on April 16. Zydus is currently evaluating the impact on its operations and the legal remedies available, including a likely appeal. It clarified that no settlement negotiations were in progress, as the matter is purely a patent dispute.
Unfavourable US court order may delay or block Zydus's generic mirabegron launch in the US, weighing on near-term sentiment. However, the company still has legal remedies open, and the final financial impact remains under assessment.